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Abstract
Background—Inflammation may be a link between depressive symptoms and outcomes in
patients with heart failure (HF). It is not clear whether inflammatory markers are independently
related to depressive symptoms in this population.
Aim—To determine which inflammatory biomarkers are independently associated with
depressive symptoms in HF.
Methods and Results—We analyzed data from 428 outpatients enrolled in a HF registry (32%
female, 61 ± 12 years, 48% NYHA Class III/IV). Depressive symptoms were measured with the
Beck Depression Inventory-II. Serum C-reactive protein (CRP), cytokines (interleukin [IL] 1RA,
2, 4, 6, 8, 10), tumor necrosis alpha, and soluble receptors sTNFR1 and sTNFR2 were measured
with enzyme immunoassay. Multiple regressions were used to determine which biomarkers were
associated with depressive symptoms controlling for demographics, HF severity, and clinical
variables. Twenty-seven percent (n = 119) had depressive symptoms. CRP was related to
depressive symptoms after controlling for age and gender, but no inflammatory biomarkers were
associated with depressive symptoms after controlling for all variables in the model.
Conclusions—There was no relationship between inflammatory biomarkers and depressive
symptoms. Our findings, in combination with prior researchers, suggest there is not a robust
relationship between depressive symptoms and individual biomarkers of inflammation in HF.
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The purpose of this study was to examine the relationship between depressive symptoms and
inflammatory biomarkers in patients with heart failure (HF). Patients with HF frequently
experience depressive symptoms that contribute to poor outcomes. One in five patients with
HF has major depressive disorder1, and an even higher proportion of patients—up to 50%—
experience clinically significant depressive symptoms as assessed by self-report
questionnaires.2 Importantly, patients with HF and depressive symptoms are twice as likely
to be re-hospitalized or die compared to patients with no depressive symptoms.1
Although a large body of research has provided evidence that depressive symptoms
independently predict morbidity and mortality in patients with HF, the biobehavioral
mechanisms underlying this relationship remain poorly understood. Researchers have
proposed that inflammation may be a link between depressive symptoms and worse health
outcomes in HF.3 Patients with HF have high levels of inflammatory cytokines such as
tumor necrosis factor-alpha (TNFα) and interleukin 6 (IL-6), which are independent
predictors of HF exacerbations and HF-related death.4–6 Clinical depression is also
accompanied by an increase in proinflammatory cytokine levels. In 2009, Howren et al.7
conducted a meta-analysis of 136 studies and found that higher levels of inflammatory C-
reactive protein (CRP), IL-1, and IL-6 were associated with depression in both community
and clinical samples, including patients with coronary artery disease.
Seven groups of researchers have examined levels of inflammation in patients with HF with
and without depressive symptoms.8–14 In the largest study on inflammation and depression
in HF to date (N = 517), Johannson et al.8 found that a combined measure of CRP and IL-6
was a positive predictor of depressive symptoms at baseline but a negative predictor of
depressive symptoms at 18 months, after controlling for severity of HF. Other inflammatory
biomarkers that have been associated with depression in patients with HF include TNFα,12
soluble receptors sTNFR19 and sTNFR2,10 and TNFα/IL-10.11 However, four of these
seven studies had sample sizes less than 40.11–14 Furthermore, there has been little
consistency between various researchers’ findings. Therefore, we examined a panel of
inflammatory biomarkers in a large sample of outpatients with HF with and without
depressive symptoms.
Our specific aims were to 1) compare levels of inflammatory biomarkers between patients
with depressive symptoms and without depressive symptoms, and 2) determine whether
inflammatory biomarkers are independently related to depressive symptom levels before and
after controlling for demographics, functional status, and clinical variables including body
mass index. We hypothesized there would be an independent relationship between
inflammatory biomarkers and depressive symptoms.
Methods
Design and Sample
This was a cross-sectional, secondary data analysis of data from the HF Quality of Life
registry. A detailed summary of registry methods has been previously published.15, 16 The
present subset (N = 428) includes a convenience sample of outpatients from three registry
studies who had baseline data on depressive symptoms and at least one inflammatory
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biomarker. The purpose of the first study was to test the effects of biofeedback and cognitive
therapy on HF outcomes (National Institutes of Health/National Institutes of Nursing
Research R01NR 008567). The second study was a prospective study in which investigators
evaluated mechanisms linking depression to worse outcomes in patients with HF. In the
third study, investigators examined the effects of body mass index on survival in patients
with HF. All three studies took place in the Southeastern United States.
All three studies selected for this data analysis used the same inclusion and exclusion
criteria. Patients were eligible for inclusion if they had a diagnosis of chronic HF, preserved
or non-preserved systolic function, taking stable medications for 3 months, and English-
speaking. Patients were excluded for a myocardial infarction or unstable angina in the past 3
months, cognitive impairment, placement at a skilled nursing facility, or severe psychiatric
impairment other than depression or anxiety.
As this was a secondary data analysis, the sample size for each of the biomarkers was
different because we were limited by the data collected in each sub-study. For each of the
sub-studies that were included in this data analysis, we consciously recruited samples that
were very similar—each study had the same inclusion/exclusion criteria, and we have
previously found that there are no significant differences in clinical or demographic
variables from each of the sub-studies used in this data analysis.
Protocol
This investigation conforms to the principles outlined in the Declaration of Helsinki. Local
institutional review boards approved the individual studies, and all patients provided written
informed consent. Baseline assessments were conducted at General Clinical Research
Centers. After completion of each study, data were de-identified and integrated into a single
database. The review board at the first author’s institution approved secondary data analysis
with this dataset as an exempt protocol.
Measurement
Demographics and clinical variables—To completely describe the sample and obtain
data on potential confounding variables, the following information was collected by patient
interview and chart review: age, sex, race/ethnicity, marital status, education level, and time
since diagnosis. The following clinical characteristics were collected by chart review:
smoking status, ejection fraction, and medications. Height and weight were measured during
the baseline visit. Data on comorbidites were collected by chart review and patient interview
using the Charlson Comorbidity Index.17, 18
Depressive symptoms—Depressive symptoms were measured using the Beck
Depression Inventory-II (BDI-II). The BDI-II is a 21-item questionnaire that assesses the
presence and severity of depressive symptoms. A score of 14 or greater indicates the
presence of clinically significant depressive symptoms. The reliability and validity of the
BDI-II has been supported in both medical and non-medical populations.19, 20
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Inflammatory biomarkers—Serum C-reactive protein (CRP), interleukins- (IL) 1
receptor antagonist (RA), 2, 4, 6, 8, and 10), TNFα, sTNFR1 and sTNFR2 were drawn by
venipuncture at a standardized time of day and measured with enzyme-linked immunoassay.
Blood was centrifuged within 30 minutes. Serum was placed in aliquotes and stored at
−70°C until analyzed in the same General Clinical Research Center core laboratory.
Samples were run in duplicate and the amount determined from standard curves using a 4-
parameter curve fit. Any samples with intra-assay coefficient of variations >10% were rerun
with subsequent acceptable coefficient of variations.
Functional status—New York Heart Association (NYHA) functional class is a subjective
indicator of functional status and was determined by patient interview.21 Patients were
assigned a classification of I (ordinary physical activity causes no symptoms of fatigue,
dyspnea, angina or palpitations), II (symptoms with ordinary physical activity), III
(symptoms occur with less than ordinary physical activity) or IV (symptoms occur even at
rest).
Covariates—Covariates included in the final regression model were age, gender, NYHA
classification, chronic obstructive pulmonary disease (COPD), current smoking status,
cholesterol lowering drugs, and body mass index. Age, sex, and body mass index were
included as covariates because each of these variables are associated with
inflammation. 7,22–23 The use of statin drugs can lower levels of CRP, TNFα, IL-1, and
IL-6.24 We did not have information on statin drugs, so we included cholesterol lowering
drug use as a proxy measure for statin use. COPD and smoking status were included as
confounders because of their bivariate associations with depressive symptoms. Finally, we
included NYHA Class because worse functional status is associated with both
inflammation25 and depression.26 We chose not to include antidepressants in the regression
because antidepressants can serve as a proxy-measure for depressive symptoms, and the
dependent variable in the regression was depressive symptoms.
Data Analysis
Data analysis was conducted using SPSS v. 20 (SPSS Inc, Chicago). All continuous
biomarker data are reported as the median (25th percentile, 75th percentile). Logarithmic
transformations were used to transform CRP, sTNFR2, IL-1ra, IL-6, and IL-8. Log
transformation did not result in a normal distribution for sTNFR1; instead, we used the
formula 1/(x + .05). We compared between-group differences in circulating levels of the
transformed data using independent t-tests. There were four biomarkers that could not be
transformed adequately using any method (TNF-α, IL-2, IL-4, and IL-10). We used the non-
parametric Mann Whitney U test to compare group differences in these biomarkers. Three
biomarkers (IL-2, IL-4, and IL-10) had a few extreme outliers; for these biomarkers we
excluded values outside the 95th% in all analyses. Chi-square tests were used to compare the
proportion of patients with and without depressive symptoms who had biomarker levels
above the median and 75th percentile.
Individual hierarchical multiple regressions were used to determine which biomarkers were
associated with levels of depressive symptoms (the dependent variable) before and after
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controlling for demographics, HF severity, and clinical variables. One biomarker was
included in each regression model. BDI-II was the dependent variable, with independent
variables entered as follows: Step 1, individual biomarker; Step 2, age and gender; Step 3,
NYHA Class I/II or III/IV; and Step 4, COPD, cholesterol lowering agents, smoking status
(current smoker: yes or no) and body mass index. An alpha of 0.05 was set a priori. For
biomarkers that could not be transformed for parametric analysis (TNF-α, IL-2, IL-4, and
IL-10), the median cut-point was used to create a categorical variable for high or low levels.
Preliminary analyses were conducted to ensure no violation of the assumptions of normality,
linearity, multicollinearity and homoscedasticity.
Results
Sample characteristics
The final sample consisted of 436 outpatients with HF, one-third of whom were female.
Most patients had stable HF—the median time since the last HF hospitalization was 24
months, and only 4% had been hospitalized in the past month. Approximately half of the
sample was classified as NYHA functional class III or IV, and one-fourth of the patients
were taking antidepressants. In Table 1, the baseline characteristics of the overall sample
and patients with (n = 119) and without depressive symptoms (n = 317) were compared.
Patients with depressive symptoms were younger and had fewer years of education
compared to patients without depressive symptoms. There was a higher percentage of
patients with depressive symptoms who had NYHA class III or IV HF (69% vs. 39%, p < .
001), were current smokers (28% vs. 16%, p = .007), and had a history of chronic
obstructive pulmonary disease (23% vs. 13%, p = .009). Among patients with depressive
symptoms, 43% were taking antidepressants, compared to 17% of patients without
depressive symptoms (p < .001). Median time since last HF hospitalization was shorter in
the patients with depressive symptoms (14 months vs. 30 months, p = .001).
Differences in biomarker levels between the two groups
Table 2 presents median biomarker levels for the overall sample and a comparison between
patients with and without depressive symptoms. There were no significant differences in
median levels of inflammatory biomarkers between the groups. There was a trend towards
higher levels of CRP (median 3.67 [25th percentile = 1.86, 75th percentile = 9.27] vs. 2.71
[1.45, 6.12], p = .071) in patients with depressive symptoms. A higher proportion of patients
with depressive symptoms had CRP values above the median (66% vs. 44%, p = .014), and
there was a trend towards a higher proportion of patients with depressive symptoms who had
sTNFR2 levels above the 75th percentile (33% vs. 24%, p = .06).
Regression results
None of the inflammatory biomarkers were independently associated with depressive
symptoms after controlling all the variables in the model (Table 3). In both the unadjusted
analysis and after controlling for age and gender, CRP was associated with depressive
symptoms (p = .004 and 07). However, after adjusting for NYHA class, CRP was no longer
significant. Soluble receptors TNFR1 and 2 were significantly associated with depressive
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symptoms during step 2 of the regression (p = .01 and .03), but were no longer significant
after NYHA class was entered into the model.
Discussion
Surprisingly, we found that none of the inflammatory biomarkers were independently
associated with depressive symptoms. Although there was a bivariate relationship between
CRP and depressive symptoms, this relationship did not continue after controlling for
functional class. At first glance, it appears that our results were not consistent with previous
researchers’ findings. However, 4 of the prior studies were limited by very small sample
sizes. When our results are compared with the 3 studies with larger sample sizes, some
similarities are noted.
Johannson et al8 reported that higher levels of IL-6 and CRP during a HF hospitalization
were positively associated with depressive symptoms at baseline (N = 517). Furthermore,
high levels of IL-6 and CRP at baseline were associated with lower levels of depressive
symptoms 18 months later. Although statistically significant, the relationships that they
identified were very small—the standardized betas were 0.18 and −0.18, respectively. Our
study differs from Johannson et al.’s in that we measured depressive symptoms and
inflammation at one time point in stable outpatients, while they enrolled patients during a
hospitalization and followed them prospectively. However, our negative study findings,
along with Johannson et al.’s finding of only a small effect, suggest that the relationship
between inflammation and depression is not as robust as some researchers have proposed.
In another large study, Moorman et al.9 measured TNFα, sTNFR1, sTNFR2, CRP, IL-1β,
IL-1ra, IL-6, IL-6r, IL-8, IL-10 in 129 outpatients with HF. Out of this panel of biomarkers,
sTNFR1 was the only biomarker in which higher quartiles were independently associated
with major depression and depressive symptoms, after controlling for age, gender, ejection
fraction, systolic blood pressure, NYHA class, HF severity (Seattle HF model score),
creatinine level, and spironolactone use. Depressive symptoms were not associated with any
of the other inflammatory biomarkers. Interestingly, although Moorman et al. found that the
highest quartile of sTNFR1 was a significant predictor of depressive symptoms compared to
the lowest quartile of sTNFR1 after controlling for NYHA class (OR 3.5, p = .005) , it did
not in our sample that was almost 3 times larger. The potential reasons for the disconnect
between our findings and those of Moorman et al. are not clear. One might think that that we
would find a significant relationship between CRP, sTNFR1, and sTNFR2 if we too entered
these biomarkers as quartiles into the regression models. However, upon doing this in a
post-hoc analysis, we still found no independent relationship between the biomarkers and
depressive symptoms. Regardless, we did have one finding in common with Moorman et al.
—we both found no evidence of a relationship between most markers of inflammation and
depressive symptoms in patients with HF.
Similarly, Kupper et al.10 measured TNF-α, IL-1ra, sTNFR1, sTNFR2, IL-6, CRP in 125
outpatients with HF. Out of this panel of biomarkers, sTNFR1 and IL-1Ra were the only
ones independently and positively associated with cognitive-affective symptoms of
depression, and sTNFR2 was the only marker positively associated with somatic-affective
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depressive symptoms. However, although statistically significant, the size of these
relationships were small (standardized beta = 0.20, 0.28, 0.21, respectively). When the data
were examined prospectively, baseline cognitive-affective symptoms of depression—but not
somatic-affective symptoms—were a positive predictor of sTNFR1 and sTNFR2 at 12
months, but again, the size of the relationships were small (standardized beta = 0.21, 0.25).
Although we used the same instrument to measure depressive symptoms—the Beck
Depression Inventory-II—our study differed from that of Kupper et al.’s in that we did not
differentiate between cognitive-affective and somatic-affective symptoms of depression, and
we chose to use depressive symptoms as our dependent variable rather than an independent
variable. Yet still, our results shared a common link in that most markers of inflammation
were not independently related to depressive symptoms.
Our study was not designed to determine whether inflammation is the mechanistic link
between depressive symptoms and poor outcomes in patients with HF. However, based on
our findings and results from prior investigators, it seems that levels of most inflammatory
cytokines are not substantially higher in patients in patients with HF and depressive
symptoms. Thus it is possible that inflammation may not be the major biological link
between depressive symptoms and poor outcomes in HF. Prospective research studies are
needed to evaluate the relationship between depressive symptoms, inflammation, and
survival outcomes in patients with HF. Furthermore, we suggest researchers determine
whether behavioral mechanisms, such as medication adherence, compose the major link
between depressive symptoms and poor outcomes.
Limitations
Because this study was cross-sectional, we cannot determine causality. Furthermore, the
pathophysiology of heart failure and inflammation are complex, thus it may be an
oversimplification to use analytic strategies that only examine one biomarker at a time.
Future research is needed to measure inflammation and depression prospectively in patients
with HF, and to examine effects of the elevation of multiple inflammatory biomarkers. Our
study was also limited by the use of self-report questionnaires to measure depressive
symptoms. Future research would benefit from the use of both diagnostic interviews and
depression questionnaires. In our study, we included patients with both preserved and non-
preserved ejection fraction, as well as patients with NYHA Class I-IV, who may have
different responses to depression. However, we also see this inclusion of the varying types
and severity of HF as strength, because we are better able to generalize our findings to
people with non-preserved and preserved systolic function HF, as well as to people with
different levels of HF severity.
Conclusions
In conclusion, we found no independent relationships between inflammatory biomarkers and
depressive symptoms at baseline. Our findings suggest there is not an independent
relationship between depressive symptoms and single biomarkers of inflammation in this
population. Additional research is needed to prospectively examine the relationship between
depressive symptoms, inflammation, behavior, and survival in patients with HF, to
determine the mechanistic link between depression and poor outcomes in this population.
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• Depression levels are high in patients with heart failure
• HF patients with depression have shorter survival times
• Inflammation may be why there are worse outcomes in HF
• However, depression and inflammation were not related in this study
• Research is needed on the link between depression and outcomes
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Female, % 31.7 30 36 .22
Age 61.1 ± 11.6 62.6 ± 11.9 57.1 ± 9.8 <.001
Married, % 53 55 47 .16
Minority, % 22 24 18 .18
BDI-II 10.3 ± 8.3 6.2 ± 3.7 21.4 ± 7.2 <.001
Body Mass Index 31.4 ± 7.3 31 ± 7.2 32.5 ± 7.6 .07
NYHA functional class, %
  Class I 10 12 5 <.001
  Class II 42 49 26
  Class III 39 33 53
  Class IV 9 6 16
Ejection fraction (%) 35 ± 14 34.5 ± 14 36.3 ± 14.7 .26
Non-preserved systolic function (Ejection
fraction < 40%)
36 35 39 .66
Ischemic HF etiology, % 49 50 46 .5
Education level (# years) 13.5 ± 3.4 13.9 ± 3.3 12.4 ± 3.3 <.001
Current smoker, % 19 16 28 .005
Months since diagnosed with HF (reported
as median, 25th %, 75th %)
60 (24, 110) 60 (23, 112) 52 (24, 105) .73
Months since hospitalized with HF
(reported as median, 25th %, 75th %)
24 (6, 84) 30 (8, 107) 14 (4, 36) .001
Comorbidities, %
  Diabetes 42 40 45 .35
  Chronic obstructive pulmonary disease 15 13 23 .009
  Implanted cardiac defibrillator 47 46 48 .78
  Stroke 20 19 24 .32
  Atrial fibrillation 43 43 44 .96
Medications, %
  Angiotensin Converting Enzyme inhibitor 70 72 65 .09
  Angiotensin receptor blocker 17 16 20 .26
  Digoxin 23 24 23 .84
  Cholesterol lowering agent 71 71 71 .89
  Diuretic 73 73 74 .81
  Beta blocker 87 88 86 .61
  Antidepressant 24 17 43 <.001
*
Data are given as mean ± SD unless otherwise indicated
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†
p values were calculated using independent t tests for continuous variables, the Mann Whitney U test for non-parametric data (months since HF
hospitalization and months since HF diagnosis), and the chi-square test of independence for categorical variables
Abbreviations: BDI-II = Beck Depression Inventory version II; NYHA = New York Heart Association; HF = heart failure
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